Biovance Capital
Overview
Biovance Capital is a prominent life sciences venture capital firm based in Lisbon, Portugal, dedicated to investing in early-stage biotech companies across Europe. The firm manages Biovance Capital Fund I, a €60 million fund supported by the European Investment Fund (EIF), Banco Português de Fomento, the European Commission through the Portugal Tech and InvestEU programmes, and private investors from Portugal and abroad. The fund focuses on seed and Series A investments, with ticket sizes ranging from €1.5 to €6 million, targeting companies developing novel transformational therapies across all disease areas and drug modalities. The firm's investment strategy emphasizes a special focus on Southern Europe, including Portugal, Spain, and Italy, aiming to support the development of innovative therapeutics in these regions. Biovance Capital works closely with entrepreneurs to build leading companies with transformative treatments for patients in need. The firm has developed a wide network across Europe, including research institutes, incubators, and accelerators, providing access to a rich pipeline of potential investments. Biovance Capital's portfolio includes notable investments such as Mondego Bio, a Portuguese startup developing breakthrough cancer treatments. In June 2025, the firm secured an investment from BIAL, Portugal's largest pharmaceutical company, bringing the fund's total size to €57 million. This partnership with BIAL enhances the fund's industry connections and technical expertise, strengthening the biotech ecosystem in Europe by providing both capital and industry knowledge to accelerate the development of transformative medicines for patients. Biovance Capital's team comprises experienced professionals with backgrounds from leading institutions such as Harvard Medical School, MIT, and Imperial College. Their expertise and commitment to supporting innovative biotech companies contribute to the firm's mission of advancing healthcare through strategic investments in early-stage drug development companies across Europe.
Investment Focus
- Companies developing novel transformational therapies
- Focus on early-stage biotech companies
- Special emphasis on Southern Europe (Portugal, Spain, Italy)
Portfolio Companies
Reach Biovance Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Biovance Capital
What sectors does Biovance Capital invest in?
Biovance Capital invests in Healthcare, Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology and Regenerative Medicine, and is based in Lisboa, Portugal. Biovance Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does Biovance Capital invest at?
Biovance Capital backs companies at Seed and Series A, writing cheques of 1.5M - 6M.
Which regions does Biovance Capital invest in?
Biovance Capital invests across United Kingdom, Germany, France, Italy, Denmark and Switzerland.
Who are the partners at Biovance Capital?
Team members listed for Biovance Capital include Ricardo Henriques (Managing Partner and Co-Founder) and André Albergaria (Co-Founder & Principal).
What companies has Biovance Capital invested in?
Biovance Capital's portfolio includes Mondego Bio.
How do I contact Biovance Capital?
Biovance Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
